Literature DB >> 22221521

The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy.

Xavier Durand1, Evanguelos Xylinas, Camelia Radulescu, Rachel Haus-Cheymol, Stephane Moutereau, Gillaume Ploussard, Aurelien Forgues, Grégoire Robert, Francis Vacherot, Sylvain Loric, Yves Allory, Alain Ruffion, Alexandre de la Taille.   

Abstract

UNLABELLED: Study Type - Diagnostic (exploratory cohort) Level of Evidence 2b What's known on the subject? and What does the study add? PCA3 scores correlate to numerous histoprognostic factors, specifically tumour volume and positive surgical margins. These results may have a clinical impact in the near future on the selection of patients eligible to undergo active surveillance and nerve-sparing surgery.
OBJECTIVE: To assess correlations between Prostate CAncer gene 3 (PCA3) levels and pathological features of radical prostatectomy (RP) specimens, which define cancer aggressiveness. PATIENTS AND METHODS: After digital rectal examination (DRE), first-catch urine was collected from 160 patients with localized prostate cancer. The PCA3 score was calculated using the Gene Probe Progensa(™) assay. PCA3 scores were then correlated to the pathological features of the RP specimens.
RESULTS: PCA3 scores correlated significantly with tumour volume (r= 0.34, P < 0.01). A PCA3 score of >35 was an independent predictor in a multivariate analysis of a tumour volume >0.5 mL (odds ratio [OR] 2.7, P= 0.04). It was also an independent predictor of positive surgical margins (OR 2.4, P= 0.04). Receiver-operator characteristic curves indicated PCA3 as the most accurate predictor of positive margins (area under the curve [AUC] 0.62), in addition to a positive biopsy percentage (AUC 0.52). There was also a significant difference in the mean PCA3 score between Gleason score patient groups (6 vs ≥ 7) and pathological stage groups (pT0/2 vs pT3/4).
CONCLUSIONS: PCA3 scores correlate to numerous histoprognostic factors, specifically tumour volume and positive surgical margins. These results may have a clinical impact in the near future on the selection of patients eligible to undergo active surveillance and nerve-sparing surgery.
© 2012 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22221521     DOI: 10.1111/j.1464-410X.2011.10682.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.

Authors:  Tian-Bao Huang; Chuan-Peng Dong; Guang-Chen Zhou; Sheng-Ming Lu; Yang Luan; Xiao Gu; Lei Liu; Xue-Fei Ding
Journal:  Int Urol Nephrol       Date:  2017-02-10       Impact factor: 2.370

Review 2.  High-risk prostate cancer-classification and therapy.

Authors:  Albert J Chang; Karen A Autio; Mack Roach; Howard I Scher
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

3.  Additional value of PCA3 density to predict initial prostate biopsy outcome.

Authors:  A Ruffion; P Perrin; M Devonec; D Champetier; M Decaussin; P Paparel; V Vlaeminck-Guillem
Journal:  World J Urol       Date:  2014-02-06       Impact factor: 4.226

Review 4.  Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score.

Authors:  Yue Wang; Xiao-Jun Liu; Xu-Dong Yao
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

5.  Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.

Authors:  John V Hegde; Darlene Veruttipong; Jonathan W Said; Robert E Reiter; Michael L Steinberg; Christopher R King; Amar U Kishan
Journal:  Urology       Date:  2017-05-25       Impact factor: 2.649

Review 6.  An emerging understanding of long noncoding RNAs in kidney cancer.

Authors:  Shuigen Zhou; Jiandong Wang; Zhengyu Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-11       Impact factor: 4.553

Review 7.  PCA3 in the detection and management of early prostate cancer.

Authors:  Xavier Filella; Laura Foj; Montserrat Milà; Josep M Augé; Rafael Molina; Wladimiro Jiménez
Journal:  Tumour Biol       Date:  2013-03-16

Review 8.  Prostate specific antigen: the past, present and future.

Authors:  Harcharan Gill; Jonathan Wu
Journal:  Curr Urol       Date:  2013-02-08

Review 9.  PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer.

Authors:  Zheng Yang; Lu Yu; Zhe Wang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

10.  Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.

Authors:  Allison Young; Nallasivam Palanisamy; Javed Siddiqui; David P Wood; John T Wei; Arul M Chinnaiyan; Lakshmi P Kunju; Scott A Tomlins
Journal:  Am J Clin Pathol       Date:  2012-11       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.